Contact this trialFirst, we need to learn more about you.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor
Empagliflozin for Heart Failure
Recruiting0 awardsPhase 1
New Haven, Connecticut
This trial tests empagliflozin in patients with worsening heart failure to see if it can help by removing extra sugar and salt from their bodies. The study includes patients with or without diabetes. Empagliflozin has been shown to reduce mortality and hospitalization for heart failure in diabetic patients.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service